Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be diagnosed with a single organ involvement such as lupus nephritis.
It is predominantly diagnosed in females of childbearing age.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.
In systemic lupus erythematosus (SLE) patients treated with hydroxychloroquine (HCQ), longer duration of use and higher cumulative dose, as well as lower creatinine clearance and geographical origin from sub-Saharan Africa and West Indies, appear to be associated with an increased risk of treatment-related retinopathy, as reported in a study.
In the treatment of active systemic lupus erythematosus (SLE), early administration of belimumab especially in patients with low damage at baseline is likely to lead to remission and low-disease activity (LDA), according to real-world data.
The type I interferon receptor subunit 1 mAb* anifrolumab significantly improves response in patients with systemic lupus erythematosus (SLE) in the second phase III randomized trial of the drug, TULIP-2** — in contrast to the first trial.
Use of ustekinumab in the treatment of systemic lupus erythematosus leads to significant improvements in many of the efficacy indices evaluated, with lower risk of flares and sustained response rates, when compared with placebo, according to 1-year data from a phase II trial.
Among Filipino patients with systemic lupus erythematosus (SLE), the use of immunosuppressive and corticosteroid contributes to an increased risk of developing herpes zoster infection, a study has found. The risk is even higher in lupus nephritis patients exposed to intravenous cyclophosphamide and mycophenolate mofetil.
Belimumab for systemic lupus erythematosus (SLE) has demonstrated a stable safety profile over 8 years of follow-up, with no new safety signal and minimal organ damage progression, according to data from an extension study involving non-American patients who completed the phase III BLISS*-52 or BLISS-76 trials.
Advanced chronic kidney disease (CKD) associated with lupus nephritis (LN) does not necessarily lead to a need for dialysis, suggests a study, which shows majority of its patients (62 percent) not progressing over 10 year of follow-up on average.